CL2015002442A1 - Uso de derivados de pirazolopirimidina para el tratamiento de trastornos relacionados con la pi3kd - Google Patents

Uso de derivados de pirazolopirimidina para el tratamiento de trastornos relacionados con la pi3kd

Info

Publication number
CL2015002442A1
CL2015002442A1 CL2015002442A CL2015002442A CL2015002442A1 CL 2015002442 A1 CL2015002442 A1 CL 2015002442A1 CL 2015002442 A CL2015002442 A CL 2015002442A CL 2015002442 A CL2015002442 A CL 2015002442A CL 2015002442 A1 CL2015002442 A1 CL 2015002442A1
Authority
CL
Chile
Prior art keywords
treatment
thymphylosthetic
pi3kd
disorders related
pyrazolopyrimidine derivatives
Prior art date
Application number
CL2015002442A
Other languages
English (en)
Spanish (es)
Inventor
Wenqing Yao
Yun-Long Li
Wenyu Zhu
Song Mei
Joseph Glenn
Andrew P Combs
Eddy W Yue
Jr Thomas P Maduskuie
Richard B Sparks
Brent Douty
Chunhong He
Original Assignee
Incyte Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Incyte Corp filed Critical Incyte Corp
Publication of CL2015002442A1 publication Critical patent/CL2015002442A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CL2015002442A 2013-03-01 2015-08-31 Uso de derivados de pirazolopirimidina para el tratamiento de trastornos relacionados con la pi3kd CL2015002442A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361771480P 2013-03-01 2013-03-01

Publications (1)

Publication Number Publication Date
CL2015002442A1 true CL2015002442A1 (es) 2016-02-05

Family

ID=50288319

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2015002442A CL2015002442A1 (es) 2013-03-01 2015-08-31 Uso de derivados de pirazolopirimidina para el tratamiento de trastornos relacionados con la pi3kd

Country Status (32)

Country Link
US (6) US9932341B2 (enExample)
EP (3) EP2961410B1 (enExample)
JP (5) JP6545106B2 (enExample)
KR (5) KR20240152422A (enExample)
CN (2) CN109010343A (enExample)
AR (1) AR094964A1 (enExample)
AU (5) AU2014223257B2 (enExample)
BR (1) BR112015020941A2 (enExample)
CA (1) CA2901993C (enExample)
CL (1) CL2015002442A1 (enExample)
CR (1) CR20150472A (enExample)
CY (1) CY1122712T1 (enExample)
DK (1) DK2961410T3 (enExample)
EA (2) EA201591612A1 (enExample)
ES (2) ES2945212T3 (enExample)
HR (1) HRP20200263T1 (enExample)
HU (1) HUE047719T2 (enExample)
IL (6) IL311666B1 (enExample)
LT (1) LT2961410T (enExample)
MX (2) MX367713B (enExample)
MY (1) MY177875A (enExample)
PE (1) PE20151996A1 (enExample)
PH (3) PH12021552233A1 (enExample)
PL (1) PL2961410T3 (enExample)
PT (1) PT2961410T (enExample)
RS (1) RS59958B1 (enExample)
SG (3) SG10201912275YA (enExample)
SI (1) SI2961410T1 (enExample)
SM (1) SMT202000043T1 (enExample)
TW (5) TWI736135B (enExample)
UA (1) UA119641C2 (enExample)
WO (1) WO2014134426A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11926630B2 (en) 2017-10-18 2024-03-12 Incyte Corporation Tertiary alcohols as PI3K-γ inhibitors
US12173006B2 (en) 2018-09-05 2024-12-24 Incyte Corporation Crystalline forms of a phosphoinositide 3-kinase (PI3K) inhibitor

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2448938B9 (en) 2009-06-29 2015-06-10 Incyte Corporation Pyrimidinones as pi3k inhibitors
MX389479B (es) 2011-09-02 2025-03-20 Incyte Holdings Corp Heterociclilaminas como inhibidores de fosfoinositida 3-cinasas (pi3k)
AR090548A1 (es) 2012-04-02 2014-11-19 Incyte Corp Azaheterociclobencilaminas biciclicas como inhibidores de pi3k
EP2943485B1 (en) 2013-01-14 2017-09-20 Incyte Holdings Corporation Bicyclic aromatic carboxamide compounds useful as pim kinase inhibitors
TWI662030B (zh) 2013-01-15 2019-06-11 英塞特控股公司 適用作pim激酶抑制劑之噻唑甲醯胺及吡啶甲醯胺化合物
TWI736135B (zh) 2013-03-01 2021-08-11 美商英塞特控股公司 吡唑并嘧啶衍生物治療PI3Kδ相關病症之用途
US9556197B2 (en) 2013-08-23 2017-01-31 Incyte Corporation Furo- and thieno-pyridine carboxamide compounds useful as pim kinase inhibitors
CA3158254C (en) 2014-04-08 2024-05-21 Incyte Corporation Treatment of b-cell malignancies by a combination jak and pi3k inhibitors
US10077277B2 (en) 2014-06-11 2018-09-18 Incyte Corporation Bicyclic heteroarylaminoalkyl phenyl derivatives as PI3K inhibitors
WO2016010897A1 (en) 2014-07-14 2016-01-21 Incyte Corporation Bicyclic heteroaromatic carboxamide compounds useful as pim kinase inhibitors
US9580418B2 (en) 2014-07-14 2017-02-28 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
WO2016130501A1 (en) 2015-02-09 2016-08-18 Incyte Corporation Aza-heteroaryl compounds as pi3k-gamma inhibitors
SG10201912302VA (en) 2015-02-27 2020-02-27 Incyte Corp Salts of pi3k inhibitor and processes for their preparation
US9988401B2 (en) 2015-05-11 2018-06-05 Incyte Corporation Crystalline forms of a PI3K inhibitor
WO2016196244A1 (en) 2015-05-29 2016-12-08 Incyte Corporation Pyridineamine compounds useful as pim kinase inhibitors
AR105967A1 (es) 2015-09-09 2017-11-29 Incyte Corp Sales de un inhibidor de pim quinasa
WO2017059251A1 (en) 2015-10-02 2017-04-06 Incyte Corporation Heterocyclic compounds useful as pim kinase inhibitors
RS63359B1 (sr) 2015-11-06 2022-07-29 Incyte Corp Heterociklična jedinjenja kao inhibitori pi3k-gama
ES2995198T3 (en) 2016-01-05 2025-02-07 Incyte Corp Pyridine compounds as pi3k-gamma inhibitors
WO2017172368A1 (en) 2016-03-31 2017-10-05 Oncternal Therapeutics, Inc. Indoline analogs and uses thereof
TW201803871A (zh) 2016-06-24 2018-02-01 英塞特公司 作為PI3K-γ抑制劑之雜環化合物
NZ761680A (en) * 2017-09-08 2023-03-31 Beigene Ltd Imidazo[1,5-a]pyrazine derivatives as pi3kdelta inhibitors
TW201924683A (zh) 2017-12-08 2019-07-01 美商英塞特公司 用於治療骨髓增生性贅瘤的低劑量組合療法
UA124694C2 (uk) * 2018-01-10 2021-10-27 Ідорсія Фармасьютікалз Лтд 2,4,6,7-ТЕТРАГІДРОПІРАЗОЛО[4,3-d]ПІРИМІДИН-5-ОНОВІ ПОХІДНІ ТА СПОРІДНЕНІ СПОЛУКИ ЯК МОДУЛЯТОРИ РЕЦЕПТОРА C5A ДЛЯ ЛІКУВАННЯ ВАСКУЛІТУ ТА ЗАПАЛЬНИХ ЗАХВОРЮВАНЬ
CR20200464A (es) 2018-03-08 2021-04-14 Incyte Corp Compuestos diólicos de aminopirazina como inhibidores de pi3k-y
IL278889B2 (en) 2018-06-01 2025-11-01 Incyte Corp Dosing regimen for the treatment of pi3k related disorders
WO2020010003A1 (en) 2018-07-02 2020-01-09 Incyte Corporation AMINOPYRAZINE DERIVATIVES AS PI3K-γ INHIBITORS
TWI727392B (zh) * 2018-08-13 2021-05-11 美商基利科學股份有限公司 噻二唑irak4抑制劑
CN110833552A (zh) * 2018-08-15 2020-02-25 广西梧州制药(集团)股份有限公司 吡唑并嘧啶衍生物在治疗狼疮肾炎的用途
WO2022115120A1 (en) 2020-11-30 2022-06-02 Incyte Corporation Combination therapy with an anti-cd19 antibody and parsaclisib
US20220241411A1 (en) 2020-11-30 2022-08-04 Incyte Corporation Combination therapy with an anti-cd19 antibody and parsaclisib
CN112808550B (zh) * 2020-12-28 2021-10-01 青岛理工大学 用于海洋工程的劣化免疫仿生防护界面及制备方法
US20230190755A1 (en) 2021-12-16 2023-06-22 Incyte Corporation Topical formulations of PI3K-delta inhibitors

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5521184A (en) 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
ES2342240T3 (es) 1998-08-11 2010-07-02 Novartis Ag Derivados de isoquinolina con actividad que inhibe la angiogenia.
US6133031A (en) 1999-08-19 2000-10-17 Isis Pharmaceuticals Inc. Antisense inhibition of focal adhesion kinase expression
GB9905075D0 (en) 1999-03-06 1999-04-28 Zeneca Ltd Chemical compounds
GB0004890D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
EP1294358B1 (en) 2000-06-28 2004-08-18 Smithkline Beecham Plc Wet milling process
CN100391958C (zh) 2001-09-19 2008-06-04 安万特医药股份有限公司 化合物
PT1441737E (pt) 2001-10-30 2006-12-29 Dana Farber Cancer Inst Inc Derivados de estrutura como inibidores da actividade do receptor de tirosina cinase flt3
PE20040522A1 (es) 2002-05-29 2004-09-28 Novartis Ag Derivados de diarilurea dependientes de la cinasa de proteina
GB0215676D0 (en) 2002-07-05 2002-08-14 Novartis Ag Organic compounds
AR042052A1 (es) 2002-11-15 2005-06-08 Vertex Pharma Diaminotriazoles utiles como inhibidores de proteinquinasas
UA80767C2 (en) 2002-12-20 2007-10-25 Pfizer Prod Inc Pyrimidine derivatives for the treatment of abnormal cell growth
GB0305929D0 (en) 2003-03-14 2003-04-23 Novartis Ag Organic compounds
PE20050952A1 (es) 2003-09-24 2005-12-19 Novartis Ag Derivados de isoquinolina como inhibidores de b-raf
MXPA06014247A (es) 2004-06-10 2007-03-12 Irm Llc Compuestos y composiciones como inhibidores de la proteina quinasa.
RU2007123675A (ru) 2004-11-24 2008-12-27 Новартис АГ (CH) Комбинации ингибиторов jak
NZ592968A (en) 2006-01-17 2012-08-31 Vertex Pharma Azaindoles substituted with either triazine or pyrimidine useful as inhibitors of janus kinases consisting of JAK1, JAK2, JAK3, and TYK2
WO2009026701A1 (en) 2007-08-29 2009-03-05 Methylgene Inc. Sirtuin inhibitors
WO2009157880A1 (en) 2008-06-27 2009-12-30 S*Bio Pte Ltd Pyrazine substituted purines
AR073651A1 (es) 2008-09-24 2010-11-24 Novartis Ag Formulaciones galenicas de compuestos organicos
WO2010036380A1 (en) * 2008-09-26 2010-04-01 Intellikine, Inc. Heterocyclic kinase inhibitors
US20120046333A1 (en) 2009-04-09 2012-02-23 Oncothyreon Incorporated Methods and Compositions of PI-3 Kinase Inhibitors for Treating Fibrosis
EP2448938B9 (en) 2009-06-29 2015-06-10 Incyte Corporation Pyrimidinones as pi3k inhibitors
US8293753B2 (en) 2009-07-02 2012-10-23 Novartis Ag Substituted 2-carboxamide cycloamino ureas
AR077974A1 (es) 2009-08-28 2011-10-05 Takeda Pharmaceutical Compuestos de hexahidrooxazinopterina para uso como inhibidores de mtor
WO2011075643A1 (en) 2009-12-18 2011-06-23 Incyte Corporation Substituted heteroaryl fused derivatives as pi3k inhibitors
WO2011075630A1 (en) 2009-12-18 2011-06-23 Incyte Corporation Substituted fused aryl and heteroaryl derivatives as pi3k inhibitors
EP2558463A1 (en) 2010-04-14 2013-02-20 Incyte Corporation Fused derivatives as i3 inhibitors
US9062055B2 (en) 2010-06-21 2015-06-23 Incyte Corporation Fused pyrrole derivatives as PI3K inhibitors
JP5961187B2 (ja) 2010-12-20 2016-08-02 インサイト・ホールディングス・コーポレイションIncyte Holdings Corporation Pi3k阻害剤としてのn−(1−(置換フェニル)エチル)−9h−プリン−6−アミン
USRE47009E1 (en) 2011-02-01 2018-08-28 The Children's Hospital Of Philadelphia HDAC inhibitors and therapeutic methods using the same
US9108984B2 (en) 2011-03-14 2015-08-18 Incyte Corporation Substituted diamino-pyrimidine and diamino-pyridine derivatives as PI3K inhibitors
US9126948B2 (en) 2011-03-25 2015-09-08 Incyte Holdings Corporation Pyrimidine-4,6-diamine derivatives as PI3K inhibitors
MX389479B (es) * 2011-09-02 2025-03-20 Incyte Holdings Corp Heterociclilaminas como inhibidores de fosfoinositida 3-cinasas (pi3k)
AR090548A1 (es) 2012-04-02 2014-11-19 Incyte Corp Azaheterociclobencilaminas biciclicas como inhibidores de pi3k
TWI736135B (zh) * 2013-03-01 2021-08-11 美商英塞特控股公司 吡唑并嘧啶衍生物治療PI3Kδ相關病症之用途
US10077277B2 (en) * 2014-06-11 2018-09-18 Incyte Corporation Bicyclic heteroarylaminoalkyl phenyl derivatives as PI3K inhibitors
SG10201912302VA (en) * 2015-02-27 2020-02-27 Incyte Corp Salts of pi3k inhibitor and processes for their preparation
IL278889B2 (en) 2018-06-01 2025-11-01 Incyte Corp Dosing regimen for the treatment of pi3k related disorders
US11161838B2 (en) * 2018-11-13 2021-11-02 Incyte Corporation Heterocyclic derivatives as PI3K inhibitors

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11926630B2 (en) 2017-10-18 2024-03-12 Incyte Corporation Tertiary alcohols as PI3K-γ inhibitors
US12516065B2 (en) 2017-10-18 2026-01-06 Incyte Corporation Tertiary alcohols as PI3K-γ inhibitors
US12173006B2 (en) 2018-09-05 2024-12-24 Incyte Corporation Crystalline forms of a phosphoinositide 3-kinase (PI3K) inhibitor

Also Published As

Publication number Publication date
TWI736135B (zh) 2021-08-11
SG10201707130UA (en) 2017-10-30
PL2961410T3 (pl) 2020-05-18
EA201591612A1 (ru) 2016-05-31
IL283943B2 (en) 2023-08-01
MX2015011273A (es) 2015-12-03
KR20220143146A (ko) 2022-10-24
DK2961410T3 (da) 2020-02-17
JP2021020914A (ja) 2021-02-18
PH12019501321A1 (en) 2020-10-12
AU2014223257A1 (en) 2015-09-24
BR112015020941A2 (pt) 2017-07-18
US12152033B2 (en) 2024-11-26
US20220119393A1 (en) 2022-04-21
SG10201912275YA (en) 2020-04-29
KR20210110409A (ko) 2021-09-07
IL301180A (en) 2023-05-01
JP2025003975A (ja) 2025-01-14
KR102454308B1 (ko) 2022-10-14
JP2023036609A (ja) 2023-03-14
AU2020210278A1 (en) 2020-08-20
SG11201506654UA (en) 2015-09-29
PH12015501920B1 (en) 2016-01-18
IL240784B (en) 2020-06-30
ES2774436T3 (es) 2020-07-21
TW202333734A (zh) 2023-09-01
TW202019428A (zh) 2020-06-01
HUE047719T2 (hu) 2020-05-28
AU2022218495A1 (en) 2022-09-08
AU2018264053A1 (en) 2018-12-06
EP3632442A1 (en) 2020-04-08
US20220106318A1 (en) 2022-04-07
US20210332059A1 (en) 2021-10-28
CY1122712T1 (el) 2021-03-12
IL283943A (en) 2021-07-29
CN105120871A (zh) 2015-12-02
CR20150472A (es) 2016-01-04
TWI657090B (zh) 2019-04-21
AR094964A1 (es) 2015-09-09
IL267853B (en) 2020-03-31
SMT202000043T1 (it) 2020-03-13
IL240784A0 (en) 2015-10-29
IL274771A (en) 2020-07-30
US20140249132A1 (en) 2014-09-04
IL267853A (en) 2019-09-26
PE20151996A1 (es) 2016-01-13
IL283943B1 (en) 2023-04-01
KR102298150B1 (ko) 2021-09-07
JP2019142941A (ja) 2019-08-29
AU2020210278B2 (en) 2022-05-26
ES2945212T3 (es) 2023-06-29
KR102717616B1 (ko) 2024-10-16
MX2019010422A (es) 2019-10-15
EP4233869A2 (en) 2023-08-30
PT2961410T (pt) 2020-03-02
KR102586858B1 (ko) 2023-10-11
KR20150135327A (ko) 2015-12-02
EP2961410B1 (en) 2019-12-11
SI2961410T1 (sl) 2020-03-31
AU2018264053B2 (en) 2020-08-20
KR20230145517A (ko) 2023-10-17
JP7556010B2 (ja) 2024-09-25
LT2961410T (lt) 2020-02-10
PH12015501920A1 (en) 2016-01-18
EA202192151A1 (ru) 2021-12-31
IL311666A (en) 2024-05-01
PH12021552233A1 (en) 2022-07-18
TW201444846A (zh) 2014-12-01
JP2016510035A (ja) 2016-04-04
HRP20200263T1 (hr) 2020-05-29
CA2901993A1 (en) 2014-09-04
EP4233869A3 (en) 2023-11-01
TWI687220B (zh) 2020-03-11
US20250289823A1 (en) 2025-09-18
PH12019501321B1 (en) 2020-10-12
TWI841376B (zh) 2024-05-01
MX367713B (es) 2019-09-03
AU2022218495B2 (en) 2024-10-03
CA2901993C (en) 2023-03-07
MY177875A (en) 2020-09-24
US20190040067A1 (en) 2019-02-07
WO2014134426A1 (en) 2014-09-04
JP6545106B2 (ja) 2019-07-17
UA119641C2 (uk) 2019-07-25
TW201929860A (zh) 2019-08-01
US9932341B2 (en) 2018-04-03
AU2014223257B2 (en) 2018-11-29
JP6776399B2 (ja) 2020-10-28
JP7189185B2 (ja) 2022-12-13
CN105120871B (zh) 2018-08-10
IL311666B1 (en) 2026-05-01
AU2024287194A1 (en) 2025-01-23
CN109010343A (zh) 2018-12-18
EP3632442B1 (en) 2023-04-05
HK1221398A1 (en) 2017-06-02
TW202214254A (zh) 2022-04-16
RS59958B1 (sr) 2020-03-31
EP2961410A1 (en) 2016-01-06
KR20240152422A (ko) 2024-10-21

Similar Documents

Publication Publication Date Title
IL242273B (en) Methods and compositions for enhancing cd4+ regulatory t cells
TWD187330S (zh) 汽車
TWD163812S (zh) 車輛之頭燈
TWD166116S (zh) 車輛擋泥板
UY35500A (es) Indazoles sustituidos con heteroarilo
EP3061124A4 (en) Vertical non-planar semiconductor device for system-on-chip (soc) applications
TWD171869S (zh) 速克達摩托車
MX365916B (es) Nuevos derivados de indolizina, su procedimiento de preparación y las composiciones farmacéuticas que los contienen.
TWD166111S (zh) 速克達摩托車
DK2961410T3 (da) Anvendelse af pyrazolopyrimidinderivater til behandlingen af pi3k relaterede lidelser
EP3089845A4 (en) Five-axis machining apparatus
PT2956347T (pt) Mesa de passageiro
UY35499A (es) Indazoles sustituidos con diaminoheteroarilo
TWD180659S (zh) 車輛輪圈蓋(一)
TWD160618S (zh) 硏磨件
TWD180660S (zh) 車輛輪圈蓋(二)
PH12015502471A1 (en) Purine derivatives as cb2 receptor agonists
HRP20171882T1 (hr) Elektrolitna smjesa za elektrokemijske članke
EP3070716A4 (en) Xy table device
TWD176305S (zh) 長形構件固定用鎖片
TWD173570S (zh) 汽車用頭燈組
MX369174B (es) Proceso para la preparación de un compuesto.
IN2013MU03768A (enExample)
TWD169940S (zh) 速克達摩托車
TWD173206S (zh) 汽車用前散熱板